miR-518c

miR-518c is a microRNA-based therapeutic candidate being investigated for the treatment of Glioblastoma Multiforme (GBM). It functions as a tumor suppressor by directly binding to and negatively regulating the expression of three key oncogenic drivers: Eukaryotic Elongation Factor-2 Kinase (eEF2K), AXL receptor tyrosine kinase, and Forkhead Box M1 (FOXM1). Preclinical studies conducted by researchers at the Houston Methodist Research Institute and the University of Houston have shown that miR-518c inhibits GBM cell proliferation, migration, invasion, and spheroid formation, while inducing apoptosis and ferroptosis. Furthermore, miR-518c has demonstrated synergistic anti-proliferative effects when combined with the standard-of-care chemotherapy temozolomide in vitro.

Other names

microRNA-518cmicroRNA518cmicroRNA 518chsa-miR-518chsa-miR518chsa-miR 518c